RESEARCH DOCUMENTS

3.1_Velculescu Lab Proposal

VICTOR E. VELCULESCU, M.D., Ph.D. CURRICULUM VITAE

CURRENT POSITION

Professor of Oncology and Pathology
Co-Director of Cancer Biology
Associate Director for Precision Medicine,
Sidney Kimmel Comprehensive Cancer Center
Associate Director of Precision Medicine for inHealth Initiative,
Johns Hopkins University School of Medicine

Johns Hopkins Kimmel Cancer Center
David H. Koch Cancer Research Building

EDUCATION

1988 – 1992 Bachelor of Science, B.S., Biological Sciences, Stanford University
1992 – 1999 Doctor of Medicine, M.D., Johns Hopkins University School of Medicine
1992 – 1999 Doctor of Philosophy, Ph.D., Human Genetics and Molecular Biology,
Johns Hopkins University School of Medicine
1999 – 2001 Postdoctoral Fellowship in Oncology, Johns Hopkins University
School of Medicine

PROFESSIONAL EXPERIENCE

1989 – 1992 Undergraduate Research, Departments of Biochemistry and Pathology,
Stanford University School of Medicine
1993 – 1998 Graduate Research, Johns Hopkins University School of Medicine
1999 – 2001 Postdoctoral Fellowship, Johns Hopkins Oncology Center
2002 – 2006 Assistant Professor of Oncology
Johns Hopkins University School of Medicine
2003 – present Affiliate Faculty, McKusick-Nathans Institute of Genetic Medicine
2004 – 2013 Director, Cancer Genetics, Ludwig Center at Johns Hopkins
2006 – 2011 Associate Professor of Oncology,
Johns Hopkins University School of Medicine
2008 – present Affiliate Faculty, Biochemistry and Molecular Biology Department
Johns Hopkins University Bloomberg School of Public Health
2009 – present Co-Director of Cancer Biology, Johns Hopkins Kimmel Cancer Center
2009 – 2013 Founder and Scientific Advisory Board, Sysmex/Inostics
2010 – present Founder and Board of Directors, Personal Genome Diagnostics, Inc.
2011 – present Professor of Oncology, Johns Hopkins University School of Medicine
2013 – 2016 Board of Directors, American Association of Cancer Research
2014 – present Professor of Pathology, Johns Hopkins University School of Medicine
2015 – present Affiliate Faculty, Institute of Computational Medicine, Johns Hopkins University
2015 – present Co-Leader, Stand Up to Cancer Colorectal Cancer Dream Team
2016 – present Affiliate Faculty, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
2016 – present Co-Leader, Lung and Head and Neck Cancer Program, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine
2018 – present Associate Director for Precision Medicine, Johns Hopkins Kimmel Cancer Center
2018 – present Associate Director of Individualized Health Initiative, Johns Hopkins University School of Medicine

AWARDS AND HONORS

1989 President’s Award for Academic Excellence, Stanford University
1992 Firestone Medal for Excellence in Research, Stanford University
1992 Graduated with Honors and Distinction, Stanford University
1992 Medical Scientist Training Program Fellowship, Johns Hopkins University
1996 Dynal Literature Award, Dynal Biotech
1998 Michael Shanoff Research Award, Johns Hopkins University School of Medicine
1999 International Grand Prize Winner, Amersham & Science Young Scientist Prize
2000 Order of Merit – Cavalier, President of Romania
2001 Benjamin Baker Scholar Award, Johns Hopkins University School of Medicine
2001 “Ten Future American Classics”, Biography magazine
2003 “Brilliant Ten Young Scientists of the Year”, Popular Science
2004 Fellow, World Technology Award for Health and Medicine
2004 Pew Scholar Award, The Pew Charitable Trusts
2006 Sir William Osler Young Investigator Award, Interurban Clinical Club
2007 Judson Daland Prize, American Philosophical Society
2008 European Association of Cancer Research and Carcinogenesis Young Investigator Award
2009 American Association of Cancer Research Award for Outstanding Achievement in Cancer Research
2009 National Brain Tumor Society Founders Award
2011 Paul Marks Prize for Cancer Research, Memorial Sloan-Kettering Cancer Center
2011 Elected to Sir William Osler Interurban Clinical Club
2013 Elected as Honorary Member to Academy of Medical Sciences in Romania
2013 American Association of Cancer Research Team Science Award for Pancreatic Cancer Research
2014 American Association of Cancer Research Team Science Award for Malignant Brain Tumor Research
2014 Elected to Alpha Omega Alpha Honor Medical Society
2014 Highly Cited Researcher by Thompson Reuters ISI
2014 Ad Astra Prize for Excellence in Research in the Life Sciences
2014 Elected to American Society for Clinical Investigation (ASCI)
2015 Co-Leader, Stand Up to Cancer Colorectal Cancer Dream Team
2016 Ernst and Young Entrepreneur of the Year Award for Maryland
2017 Elected as Foreign Honorary Member to the Romanian Academy
2017 American Association of Cancer Research Team Science Award for Research in Liquid Biopsies for Cancer
2018 Elected to American Association of Physicians (AAP)
2018 Centennial Award of Excellence, Government of Romania
2018 Carol and Dick Hertzberg Prize for Technological Innovations, UCSD

RESEARCH ACTIVITIES

Contribution to Science

Dr. Velculescu is the first, corresponding, or co-corresponding author on papers cited below. Source of citation information: Google Scholar as of February 11, 2019
Total citations: 89,329
h-index: 105
1. Development of new methods for genomic analyses of human cancer. Comprehensive genomic analyses provide the basis for our current understanding of cancer. At the time we began our molecular studies in the early 1990’s essentially all analyses in cancer were performed one gene at time. In 1995, we developed SAGE (serial analysis of gene expression), a gene expression technology that allowed for global and quantitative measurement of gene activity. We applied this approach to provide the first insights into gene expression patterns in eukaryotic cells and to identify dysregulated gene expression patterns in human cancer. Through these studies I coined the term “transcriptome” in 1997 to describe the comprehensive gene expression patterns that could now be analyzed in human cancer and other cells. This approach has provided the basis for next-generation transcript sequencing methods used for genome-wide expression analyses (e.g. RNAseq). In parallel, our group has developed technologies for characterizing the cancer genome. These have included development of Digital Karyotyping, which allowed for quantitative characterization of amplifications and deletions at the DNA level in an unbiased manner. In subsequent years, variations of these approaches have been widely used to analyze genomic alterations in human cancer and other human diseases.
a. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995; 270:484-487. 5529 citations.
b. Velculescu VE, Zhang L, Zhou W, Vogelstein J, Basrai MA, Bassett D Jr, Hieter P, Vogelstein B, Kinzler KW. Characterization of the yeast transcriptome. Cell 1997;88:243-251. 1291 citations.
c. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S, Landes GM, Riggins GJ, Vogelstein B, Kinzler KW. Analysis of human transcriptomes. Nature Genetics 23: 387-8, 1999. 866 citations.
d. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, Velculescu VE. Digital karyotyping. Proc Natl Acad Sci USA 2002;99:16156-16161. 316 citations.

2. Discovery of the role of PIK3CA in human cancer. Using the genomic tools we had developed, our group performed the first sequence analyses of entire gene families in a human cancer, initially focusing on genes involved in signal transduction pathways. These included the entire set of tyrosine kinases, the serine/threonine kinases, the protein phosphatases, and lipid kinases. Through these analyses, we identified a variety of genes not previously known to be involved in human cancer. In particular, we identified a high frequency of sequence alterations in the PIK3CA gene in colorectal, breast, brain and other cancer types. These analyses and subsequent studies have identified PIK3CA as one of the most highly mutated genes in human cancer. We showed that mutations of PIK3CA are activating, promote cellular survival and invasion, and that cancer cells with these alterations can be inhibited with PI3K inhibitors. Due to its widespread involvement in human cancer, PIK3CA is one of the most frequently targeted proteins in current clinical trials.
a. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. 3167 citations.
b. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792. 585 citations.
c. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-73, 2005. 830 citations.
d. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome. Science 300:949, 2003. 538 citations.

3. Genome-wide analyses of human cancer. Our group working with colleagues at Johns Hopkins and other institutions, performed the first sequence analysis of the coding genome in human cancers, including in breast, colorectal, brain, pancreatic, head and neck, and ovarian cancers. These anlayses provide insights into the complexity of alterations in human cancer and identified changes in genes not previously known to be involved in these diseases. These included the IDH1 and IDH2 genes in gliomas, chromatin modifying genes MLL2, MLL3 and ARID1 in medulloblastomas, ovarian cancers, and neuroblastomas, and NOTCH1 alterations in head and neck cancers. In addition to inhibitors targeting PIK3CA and IDH which are already in clinical trials, we have begun to translate these analyses to the clinic, providing insights into the actionable genome as well as identifying alterations that affect response and resistance to therapuetic intervention.
a. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber T, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science. 314(5797):268-74, 2006. 3432 citations.
b. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, … Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12. PMCID: 2820389. 4558 citations.
c. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science. 2007 Nov 16;318(5853):1108-13. Epub 2007 Oct 11. PMID: 17932254 2995 citations.
d. Anagnostou V, Smith KN, Patrick PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf R, Brahmer JR, Karchin R, Pardoll DM and Velculescu, VE. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discovery, 7(3):264-276, 2017. PMID: 28031159. 154 citations

4. Liquid biopsies for non-invasive detection and characterization of human cancer. In order to translate our genomic efforts to diagnostic applications, we have developed approaches for detection of mutated DNA in the circulation of cancer patients. For this purpose, we have invented PARE (personalized analysis of rearranged ends) for personalized development of genomic biomarkers for tumor detection and monitoring. Using these approaches, we performed the first whole-genome analyses for detection of circulating tumor DNA, providing a universal approach for non-invasive detection of human cancer. More recently we developed approaches for direct detection of early stage cancers using circulating tumor DNA. These approaches have wide-spread applications in human cancer including in identification of actionable alterations, disease monitoring, therapeutic resistance, detection of residual disease, and early detection.
a. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, de la Vega, F, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. Science TM, 2: 20ra14, 2010. PMCID: PMC2858564. 450 citations.
b. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of Chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science TM. 4:162ra154, 2012 PMCID: PMC3641759. 424 citations.
c. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, … Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science TM. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. 1705 citations.
d. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE. Direct detection of early-stage cancers using circulating tumor DNA. Science TM. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/ scitranslmed.aan2415. PMID: 28814544. 117 citations.

List of Publications in NCBI MyBibliography:
http://www.ncbi.nlm.nih.gov/sites/myncbi/victor.velculescu.1/bibliography/41165259/public/?sort=date&direction=descending

Complete List of Peer Reviewed Publications:

1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
2. Dintzis SM, Velculescu VE, Pfeffer SR. Receptor extracellular domains may contain trafficking information – studies of the 300-kDa mannose 6-phosphate receptor. Journal of Biological Chemistry 269: 12159-12166, 1994.
3. El-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Research 54: 1169-1174, 1994.
4. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Research 55: 2910-19, 1995.
5. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 270: 484-487, 1995.
6. Velculescu VE and El-Deiry WS. Biological and clinical implications of the p53 tumor suppressor gene. Clinical Chemistry 42: 858-868, 1996.
7. Velculescu VE, Zhang L, Zhou W, Vogelstein J, Basrai MA, Bassett D Jr, Hieter P, Vogelstein B, Kinzler, KW. Characterization of the yeast transcriptome. Cell 88: 243-251, 1997.
8. Zhang L, Zhou W, Velculescu VE, Kern S, Hruban R, Hamilton S, Vogelstein B, Kinzler, KW. Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997.
9. Zhou W, Sokoll LJ, Bruzek DJ, Zhang L, Velculescu VE, Goldin SB, Hruban R, Kern SE, Hamilton SR, Chan DW, Vogelstein BV, Kinzler KW. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiology, Biomarkers and Prevention 7: 109-112, 1998.
10. Bertelsen AH and Velculescu VE. High throughput gene expression analysis using SAGE. Drug Discovery Today 3: 152-160, 1998.
11. Basrai, MA, Velculescu VE, Kinzler, KW, Hieter, P. NORF5/HUG1 couples DNA damage to checkpoint function. Molecular and Cellular Biology 19: 7041-7049, 1999.
12. Lal A, Lash A, Altschul S, Velculescu VE, Zhang L, McLendon R, Marra M, Prange C, Morin P, Polyak K, Papadopoulos N, Vogelstein B, Kinzler K, Strausberg R, Riggins G. A Public Database for Gene Expression in Human Cancers. Cancer Research 59: 5403-7, 1999.
13. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S, Landes GM, Riggins GJ, Vogelstein B, Kinzler KW. Analysis of human transcriptomes. Nature Genetics 23: 387-8, 1999.
14. Velculescu VE. Tantalizing Transcriptomes – SAGE and its use in global gene expression analysis. Science 286: 1491-1492, 1999.
15. St Croix B, Rago C, Velculescu VE, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes Expressed in Human Tumor Endothelium. Science 289: 1197-202, 2000.
16. Velculescu VE, Vogelstein B, Kinzler KW. Analysing uncharted transcriptomes using SAGE. Trends in Genetics 16: 423-5, 2000.
17. Howe JR, Bair JA, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein, B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nature Genetics 28:184-7, 2001.
18. Jones SJM, Riddle DL, Pouzyrev AT, Velculescu VE, Hillier L, Eddy SR, Stricklin SL, Baillie DL, Waterston R, Marra MA. Changes in Gene Expression Associated with Developmental Arrest and Longevity in Caenorhabditis elegans. Genome Research 11: 1346-1352, 2001.
19. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A Phosphatase Associated with Metastasis of Colorectal Cancer. Science 294:1343-6, 2001.
20. Wang TL, Rago C, Silliman N, Ptak J, Parmigiani G, Kinzler KW, Vogelstein B, and Velculescu VE. Prevalence of somatic alterations in the colorectal cancer genome. Proceedings of the National Academy of Sciences USA 99:3076-3080, 2002.
21. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW, Velculescu VE. Using the transcriptome to annotate the genome. Nature Biotechnology 20:508-12, 2002.
22. Yan H, Yuan W, Velculescu VE, Vogelstein B and Kinzler KW. Allelic variation in human gene expression. Science 297:1143, 2002.
23. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002.
24. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, Velculescu VE. Digital Karyotyping. Proceedings of the National Academy of Sciences USA 99:16156-16161, 2002.
25. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome. Science 300:949, 2003.
26. Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IeM. Identifying tumor origin using a gene expression-based classification map. Cancer Research 63(14):4144-9, 2003.
27. Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VE, Kinzler KW, Vogelstein B. PRL-3 expression in metastatic cancers. Clinical Cancer Research 9(15):5607-5615, 2003.
28. Rajagopalan H, Jallepalli P, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 428(6978):77-81, 2004.
29. Wang TL, Diaz LA, Romans K, Bardelli A, Saha S, Glizia G, Choti M, Donehower R, Parmigiani G, Shih I, Iacabuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-FU in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences USA 101(9):3089-94, 2004.
30. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670): 554, 2004.
31. Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, Parsons DW, Traverso G, Awad M, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz SD, Goldberg ML, Karess R, Kinzler KW, Vogelstein B, Velculescu VE and Lengauer C. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Research 64 (9): 2998-3001, 2004.
32. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, Van Der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE*. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304(5674):1164-6, 2004.
33. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, Mclendon RE, Fults DW, Velculescu VE, Bigner DD, Yan Y. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas and medulloblastomas. Cancer Research 64(15):5048-50, 2004.
34. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, and Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology and Therapy 3:8, e49-e52.
35. Samuels Y and Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 3 (10): 1221-1224, 2004.
36. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research 64(24):8816-20, 2004.
37. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. New England Journal of Medicine 351(27):2883, 2004.
38. Bardelli A, Velculescu VE. Mutational analysis of gene families in human cancer. Curr Opin Genet Dev. 15(1):5-12, 2005.
39. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research 65(3):919-24, 2005.
40. Peters BA, Velculescu VE. Transcriptome PETs: A genome’s best friends. Nature Methods 2, 93 – 94, 2005.
41. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-73, 2005.
42. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics 37, 899-905, 2005.
43. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792, 2005.
44. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjöblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE. The colorectal microRNAome. Proceedings of the National Academy of Sciences USA. 103(10):3687-92, 2006.
45. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih IM, Wang TL. Homozygous Deletion of MKK4 in Ovarian Serous Carcinoma. Cancer Biology & Therapy. 5(6):630-4, 2006.
46. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IM. Sequence Mutations and Amplification of PIK3CA and AKT2 Genes in Purified Ovarian Serous Neoplasms. Cancer Biology & Therapy. 26;5(7), 2006.
47. Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, Wang TL, Yan H, Gazdar A, Kern SE, Pennacchio L, Kinzler KW, Vogelstein B, Velculescu VE. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutation. 27(10):1060-1, 2006.
48. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber T, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science. 314(5797):268-74, 2006.
49. Edkins S, O’meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal A. Recurrent KRAS Codon 146 Mutations in Human Colorectal Cancer. Cancer Biol Ther. 5(8):928-32, 2006.
50. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 25(46):6220-7, 2006.
51. Bettegowda C, Huang X, Lin J, Cheong I, Kohli M, Szabo SA, Zhang X, Diaz LA Jr, Velculescu VE, Parmigiani G, Kinzler KW, Vogelstein B, Zhou S. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nature Biotechnology. 24(12):1573-1580, 2006.
52. Peters BA, St Croix B, Sjöblom T, Cummins JM, Silliman N, Ptak J, Saha S, Kinzler KW, Hatzis C, Velculescu VE. Large-scale identification of novel transcripts in the human genome. Genome Research 17(3):287-92, 2007.
53. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE, Wang ZJ. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A. 104(10):4060-4, 2007.
54. Velculescu VE, Kinzler KW. Gene expression analysis goes digital. Nature Biotechnology 25(8):878-80, 2007.
55. Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, Parsons DW, Papadopoulos N, Kinzler KW, Vogelstein B, Parmigiani G, Velculescu VE. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Research 17 (9):1304-18, 2007.
56. Leary RJ, Cummins J, Wang TL, Velculescu VE. Digital karyotyping. Nature Protocols. 2(8):1973-86, 2007.
57. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, Samuels Y, Velculescu VE, Vogelstein B, Kinzler KW, Diaz LA Jr. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 67(19):9364-70, 2007.
58. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW*, Velculescu VE*, Vogelstein B*. The Genomic Landscapes of Human Breast and Colorectal Cancers. Science. 318(5853):1108-13, 2007. *corresponding author
59. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. Genetic progression and the waiting time to cancer. PLoS Comput Biol. 3(11):e225, 2007.
60. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 318(5857):1744-8, 2007.
61. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 68(3):889-92, 2008.
62. Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D, Barrett I, Nouhi Y, Spencer F, Markowitz S, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C, Hieter P. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A. 105:3443-48, 2008. PMCID: PMC2265152.
63. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A. 105(11):4283-8, 2008. PMCID: PMC2393770.
64. Picelli S, Vandrovcova J, Jones S, Djureinovic T, Skoglund J, Zhou XL, Velculescu VE, Vogelstein B, Lindblom A. Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. BMC Cancer. 8:87, 2008. PMCID: PMC2324103.
65. Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis. 29(6):1087-91, 2008. PMCID: PMC2825145.
66. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 5(5):e114, 2008. PMCID: PMC2429944.
67. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B*, Velculescu VE*, Kinzler KW*. An integrated genomic analysis of human glioblastoma multiforme. Science. 321(5897):1807-12, 2008. PMCID: PMC2820389 *corresponding author
68. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B*, Velculescu VE*, Kinzler KW*. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321(5897):1801-6, 2008. PMCID: PMC2848990. *corresponding author
69. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A. 105(42):16224-9, 2008. PMCID: PMC2571022.
70. He Y, Vogelstein B, Velculescu V, Papadopoulous N, Kinzler KW. The Antisense Transcriptomes of Human Cells. Science. 322(5909):1855-1857, 2008. PMCID: PMC2824178.
71. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics. 93(1):17-21, 2009. PMCID: PMC2820387.
72. Yan H, Parsons DW, Genglin J, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine 360: 765-773, 2009. PMCID: PMC2820383
73. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin Cheng-Ho J, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigini G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein A. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science 324: 217, 2009. PMCID: PMC2684332
74. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. American Journal of Pathology. 174:1597-601, 2009. PMCID: PMC2671248
75. Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW and Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 69(8):3681-3688, 2009. PMID: 19351817 PMCID: PMC2669837
76. Duncan CG, Leary RJ, Lin JC-H, Cummins J, Di C, Schaefer CF, Wang T-L, Riggins GJ, Edwards J, Bigner D, Kopelovich L, Vogelstein B, Kinzler KW, Velculescu VE and Yan H. Identification of microbial DNA in human cancer. BMC Medical Genomics 22: 1-12, 2009. PMCID: PMC2685141
77. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons, DW, Lin J C-H, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE and Hruban RH. SMAD4 Gene Mutations are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 15(14): 4674-4679, 2009. PMCID: PMC2819274
78. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B and Karchin R. Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations. Cancer Research 69 (16): 6660-6667, 2009. PMCID: PMC2763410
79. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JKV, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, Kinzler KW, Papadopoulos N, Vogelstein B, Willis J, Gerken TA and Markowitz SD. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proceedings of the National Academy of Sciences, U.S.A. 106 (31): 12921-12925, 2009. PMCID: PMC2722285
80. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Wilson JKV, Markowitz S, Zhou S, Diaz Jr. LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N. Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. Science 325 (5947): 1555-1559, 2009. PMCID: PMC2820374
81. Li M, Chen W-D, Papapdopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, He Y, Diehl F, Velculescu VE, Zhou S, Diaz Jr. LA, Kinzler KW, Markowitz SD and Vogelstein B. Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnology 9: 858-863, 2009. PMCID: PMC2847606
82. Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Research 69:9157-9, 2009. PMID: 19996293 PMCID: PMC2794981
83. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B and Papadopoulos N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proceedings of the National Academy of Sciences, U.S.A. 107: 2598-2603, 2010. PMCID: PMC2823889
84. He Y, Wu J, Dressman D, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA Jr, Kinzler K W, Vogelstein B, Papadopoulos N. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464: 610-614, 2010. PMCID: PMC3176451.
85. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, de la Vega, F, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. Science Translational Medicine, 2: 20ra14, 2010. PMCID: PMC2858564.
86. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, … Velculescu VE, et al. International network of cancer genome projects. Nature, 15;464(7291):993-8, 2010. PMCID: PMC2902243.
87. Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B*, Kinzler KW*, Velculescu VE* and Papadopoulos N*. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science, 330(6001):228-31, 2010. PMCID: PMC3076894. *corresponding author
88. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319):1114-7, 2010. PMCID: PMC3148940.
89. Boca SM, Kinzler K, Velculescu VE, Vogelstein B, Parmigiani G. Patient-oriented gene set analysis for cancer mutation data. Genome Biol. 11(11):R112, 2010. PMCID: PMC3156951.
90. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, Gerhard DS, Fults DW, VandenBerg S, Berger MS, Marie SK, Shinjo SM, Clara C, Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, Curran T, He Y, Rasheed BA, Friedman HS, Keir ST, McLendon R, Northcott PA, Taylor MD, Burger PC, Riggins GJ, Karchin R, Parmigiani G, Bigner DD, Yan H, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439, 2010. PMCID: PMC3110744.
91. Jiao, Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH and Papadopoulos N. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science 331:1199-1203, 2011. PMCID: PMC3144496.
92. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC and Slamon DJ. Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer. Clin. Cancer Res. 17:1591-1602, 2011 PMID: 21278246.
93. Joshi AD, Parson DW, Velculescu VE and Riggins G. Sodium Ion Channel Mutations in Glioblastoma Patients Correlate with Shorter Survival. Mol. Cancer 2011. PMCID: PMC3050859.
94. Bessarabova M, Pustovalova O, Shi W, Serebriyskaya T, Ishkin A, Polyak K, Velculescu VE, Nikolskaya T and Nikolsky Y. Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Cancer Research 2011. PMID: 21398405. Journal – In Process.
95. Shih IeM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, Velculescu VE, Kurman RJ and Wang TL. Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas. Am J Pathol. 178:1442-7, 2011. PMID: 21435433 Journal – In Process.
96. Zhang X, Reis M, Khoriaty R, Li Y, Ouillette R, Samayoa J, Carter H, Karchin R, Li M, Diaz LA Jr, Velculescu VE, Papadopoulos N, Kinzler KW, Vogelstein B. and Malek SN. Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Leukemia 163, 2011. PMCID: PMC3523306.
97. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie T-X, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky S, Vogelstein B, Velculescu VE*, Papadopoulos N*, Wheeler DA*, Kinzler KW*, Myers JN*. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science, 333:1154-1157, 2011. PMCID: PMC3162986. *corresponding author
98. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJA, Velculescu VE, Wang L, Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J, Torbenson MS and Kinzler KW. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 43:828-829, 2011. PMCID: PMC3163746.
99. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SKN, Vogelstein B, Bigner D, Yan H, Papadopoulos N and Kinzler KW. Mutations in CIC and FUBP1 contribute to human oligodendrogliomas. Science, 333:1453-1455, 2011. PMCID: PMC3170506.
100. Velculescu VE, Diaz LA Jr. Understanding the enemy. Science Translational Medicine. 2011 Aug 31;3(98):98ps37. PMID: 21885403.
101. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutation 2011 Oct 18. doi: 10.1002/humu.21633. [Epub ahead of print]. PMCID: PMC 3240719.
102. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N. and Shih IM. Low-grade serous carcinomas of the ovary contain very few point mutations. J. Pathology, 226: 413-420, 2011. PMID: PMC3503448.
103. Willard, M.D., Lajiness, M.E., Wulur, I.H., Feng, B., Swearingen, M.L., Uhlik, M.T., Kinzler, K.W., Velculescu, V.E., Sjöblom, T., Markowitz, S.D., Powell, S,M., Vogelstein, B. and Barber, T.D. Somatic mutations in CCK2R alter receptor activity that promote oncogenic. Mol Cancer Res. 2012. PMID: 22516348.
104. Roberts, N.J., Vogelstein, J.T., Parmigiani, G., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. The Predictive Capacity of Personal Genome Sequencing. Sci. Transl. Med. 4: 133, 2012 PMID: 22472521
105. Roberts, NJ, Jiao, Y, Yu, J, Kopelovich, L, Petersen, GM, Bondy, ML, Gallinger, S, Schwartz, AG, Syngal, S, Cote, ML, Axilbund, J, Schulick, R, Ali, SZ, Eshleman, JR, Velculescu, VE, Goggins, M, Vogelstein, B, Papadopoulos, N, Hruban, RH, Kinzler, KW and Klein, AP. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2: 41-46, 2012. PMID: 22585167 Journal – In Process.
106. Vogelstein, B., Roberts, N.J., Vogelstein, J.T., Parmigiani, G., Kinzler, K.W. and Velculescu, V.E. Response to comments on “the predictive capacity of personal genome sequencing”. Sci Transl. Med. 4: 135lr3, 2012. PMID: 22623739 Journal – in Process.
107. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, Cheng Y, Twaddell WS, Latt NL, Shin EJ, Wang LD, Wang L, Yang W, Velculescu VE, Vogelstein B, Papadopoulos N, Kinzler KW, Meltzer SJ. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2: 899-905, 2012. PMCID: PMC3473124.
108. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 18: 4257-4265, 2012. PMCID:PMC3422771.
109. Kim MS, Kuppireddy SV, Sakamuri S, Singal M, Getnet D, Harsha HC, Goel R, Balakrishnan L, Jacob HK, Kashyap MK, Tankala SG, Maitra A, Iacobuzio-Donahue CA, Jaffee E, Goggins MG, Velculescu VE, Hruban RH, Pandey A. Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). J Proteome Res. 11: 5556-5563, 2012. PMCID: PMC3565537.
110. Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, Hruban RH, Klein AP, Jones S, Velculescu V, Wolfgang CL, Iacobuzio-Donahue CA. Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors. Clin Cancer Res. 18: 6339-6347, 2012 PMCID: PMC3500447.
111. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of Chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 4:162ra154, 2012. PMCID: PMC3641759.
112. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE*, Hogarty MD*. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 45: 12-17, 2012. PMCID: PMC3557959. *corresponding author
113. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW. Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. J Clin Endocrinol Metab. 98: E364-9, 2012. PMCID:PMC3565108.
114. Killela, P.J., Reitman, Z.J, Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L.A. Jr., Friedman, A.H., Friedman, H., Gallia, G.L., Giovanella, B.C., Grollman, A.P., He, T.C., He, Y., Hruban, R.H., Jallo, G.I., Mandahl, N., Meeker, A.K., Mertens, F., Netto, G.J., Rasheed, B.A., Riggins, G.J., Rosenquist, T.A., Schiffman, M., Shih, IeM., Theodorescu, D., Torbenson, M.S., Velculescu, V.E., Wang, T.L., Wentzensen, N., Wood, L.D., Zhang, M., McLendon, R.E., Bigner, D.D., Kinzler, K.W., Vogelstein, B., Papadopoulos, N., Yan, H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal Proceedings of the National Academy of Sciences, U.S.A., 110: 6021-6026, 2013. PMCID: PMC3625331.
115. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr. and Kinzler, K.W. Cancer genome landscapes. Science 339:1546-1558, 2013 PMID: 23539594 Journal – in Process.
116. Ihnen M, Zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer. Mol Cancer Ther. 12:1002-15, 2013. PMID:23729402. Journal – in Process.
117. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discov. 3:658-673, 2013. PMID:23729478.
118. Leary RJ, Sausen M, Diaz LA Jr, Velculescu VE. Cancer detection using whole-genome sequencing of cell free DNA. Oncotarget. 2013 Aug;4(8):1119-20.
119. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics. 2013 Dec;45(12):1470-3.
120. Diaz LA Jr, Sausen M, Fisher GA, Velculescu VE. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget. 2013 Oct;4(10):1856-7.
121. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE*, Kinzler KW*, Vogelstein B*, Papadopoulos N*, Diaz LA Jr*. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. *corresponding author
122. Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14. PubMed PMID: 24634382.
123. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clin Cancer Res. 2014 May 6. PubMed PMID: 24727326.
124. Guerrero-Preston R, Michailidi C, Marchionni L, Pickering C, Frederick M, Myers J, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D. Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancer. Epigenetics. 2014 May 1;9(7). PubMed PMID: 24786473.
125. Haber DA, Velculescu VE. Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. Cancer Discov. 2014 May 6. PubMed PMID: 24801577.
126. Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA Jr, Lengauer C, Velculescu VE. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nature Communications. 2014 Sep 19;5:5006. PubMed PMID: 25233892.
127. Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch WM, McCord C, Riley D, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res. 2014 Nov 18. PubMed PMID: 25406187.
128. Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA Jr. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014 Dec 16;2(1):42. PMID: 25516806
129. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA Jr, Velculescu VE. Personalized genomic analyses for cancer mutation discovery and interpretation. Science Translational Medicine. 2015 Apr 15;7(283):283ra53. PMID: 25877891
130. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O’Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Communications. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686. PMID: 26154128
131. Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol. 2015 Oct;139(1):97-103. doi: 10.1016/j.ygyno.2015.08.017. Epub 2015 Aug 29.
132. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.
133. Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Mol Cancer Ther. 2016 Jul;15(7):1746-56.
134. Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, Xiang M, Xu C, Fink S, Meropol NJ, Xu Y, Conlon RA, Markowitz S, Kinzler KW, Velculescu VE, Brunengraber H, Willis JE, LaFramboise T, Hatzoglou M, Zhang GF, Vogelstein B, Wang Z. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nature Communications. 2016 Jun 20;7:11971.
135. Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clinical Cancer Research. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29. PMID: 27573169
136. Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, Georgiadis A, Phallen J, Brahmer J, Azad N, Browner I, Laheru D, Velculescu VE, Sausen M, Diaz LA Jr. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clinical Cancer Research. 2016 Nov 8. doi: 10.1158/1078-0432.CCR-16-1691.
137. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discovery. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28. PMID: 28031159
138. Yeung KT, More S, Woodward B, Velculescu V, Husain H. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Mol Diagn Ther. 2017 Mar 24. doi: 10.1007/s40291-017-0260-5. [Epub ahead of print] Review. PMID: 28337711
139. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346. PMID: 28373404
140. AACR Project GENIE Consortium. André F, Arnedos M, Baras AS, Baselga J, Bedard PL, Berger MF, Bierkens M, Calvo F, Cerami E, Chakravarty D, Dang KK, Davidson NE, Del Vecchio Fitz C, Dogan S, DuBois RN, Ducar MD, Futreal PA, Gao J, Garcia F, Gardos S, Gocke CD, Gross BE, Guinney J, Heins ZJ, Hintzen S, Horlings H, Hudeček J, Hyman DM, Kamel-Reid S, Kandoth C, Kinyua W, Kumari P, Kundra R, Ladanyi M, Lefebvre C, LeNoue-Newton ML, Lepisto EM, Levy MA, Lindeman NI, Lindsay J, Liu D, Lu Z, MacConaill LE, Maurer I, Maxwell DS, Meijer GA, Meric-Bernstam F, Micheel CM, Miller C, Mills G, Moore ND, Nederlof PM, Omberg L, Orechia JA, Park BH, Pugh TJ, Reardon B, Rollins BJ, Routbort MJ, Sawyers CL, Schrag D, Schultz N, Shaw KRM, Shivdasani P, Siu LL, Solit DB, Sonke GS, Soria JC, Sripakdeevong P, Stickle NH, Stricker TP, Sweeney SM, Taylor BS, Ten Hoeve JJ, Thomas SB, Van Allen EM, Van ‘t Veer LJ, van de Velde T, van Tinteren H, Velculescu VE, Virtanen C, Voest EE, Wang LL, Wathoo C, Watt S, Yu C, Yu TV, Yu E, Zehir A, Zhang H. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1. PMID: 28572459
141. Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O’Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer. 2017 Aug 8;117(4):572-582. doi: 10.1038/bjc.2017.209. Epub 2017 Jul 18. PMID: 28720843
142. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE. Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415. PMID: 28814544
143. Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O’Hagan HM, Murphy L, Zahnow CA, Gabrielson E, Velculescu VE, Easwaran HP, Baylin SB. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell. 2017 Sep 11;32(3):360-376.e6. doi: 10.1016/j.ccell.2017.08.006. PMID: 28898697; PMCID: PMC5596892.
144. Husain H, Velculescu VE. Cancer DNA in the Circulation: The Liquid Biopsy. JAMA. 2017 Oct 3;318(13):1272-1274. doi: 10.1001/jama.2017.12131. PMID: 28973237
145. Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1. PMID: 29061967
146. Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, Strick R, Velculescu VE, Baylin SB. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017 Nov 30;171(6):1284-1300.e21. doi: 10.1016/j.cell.2017.10.022. PMID: 29195073

147. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. PMID: 29658848.
148. Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam AJ, Zhang J, El Asmar M, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll D, Housseau F, Smith KN. The Mutation-Associated Neoantigen Functional Expansion of Specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol Res. 2018 Jun 12. pii: canimm.0129.2018. doi: 10.1158/2326-6066.CIR-18-0129. [Epub ahead of print]. PMID: 29895573
149. Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218. PMID: 29982279
150. Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19. PMID: 29983880
151. Wood DE, White JR, Georgiadis A, Van Emburgh B, Parpart-Li S, Mitchell J, Anagnostou V, Niknafs N, Karchin R, Papp E, McCord C, LoVerso P, Riley D, Diaz LA Jr, Jones S, Sausen M, Velculescu VE, Angiuoli SV. A machine learning approach for somatic mutation discovery. Sci Transl Med. 2018 Sep 5;10(457). pii: eaar7939. doi: 10.1126/scitranslmed.aar7939. PMID: 30185652
152. Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, Slamon D, Velculescu VE, Scharpf RB. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Rep. 2018 Nov 27;25(9):2617-2633. doi: 10.1016/j.celrep.2018.10.096. PMID: 30485824.
153. Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone KA, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2018 Dec 12. pii: canres.1127.2018. doi: 10.1158/0008-5472.CAN-18-1127. [Epub ahead of print] PMID: 30541742
154. Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2018 Dec 20. pii: canres.1082.2018. doi: 10.1158/0008-5472.CAN-18-1082. [Epub ahead of print] PMID: 30573519
155. Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium. American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions’ Perspectives. JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083. PMID: 30652542
156. Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Mol Cancer Ther. 2019 Jan 24. pii: molcanther.0413.2018. doi: 10.1158/1535-7163.MCT-18-0413. PMID: 30679390

Book Chapters:

1. Lattin B, Velculescu V, Chen J, DiGregorio D, Zeitung J. Immunology: an introduction to experimental immunology. Introductory Experimental Biology. Eds. Yelton M and Stenfanides S. Stanford University, 1992
2. Shatzer J, Mead LA, Velculescu V, Hurt KJ, Klag MJ. Evaluation of the curriculum. The Johns Hopkins University School of Medicine Curriculum for the Twenty-first Century. Ed. Catherine DeAngelis. Johns Hopkins University Press, 1998
3. Yen MJ, Shih IM, Velculescu VE, Wang TL. Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance. Cancer Drug Resistance. Edited by Dr. Beverly A Teicher. Publisher: Human Press. New Jersey. 2006; pp 531-540.

Interviews:

1. Culliton, Barbara J. The intersection of basic science and health policy: a conversation with Victor Velculescu. Interview by Barbara J. Culliton. Health Affairs. 2008 Jan-Feb;27(1):w27-33.
2. Velculescu V, Bender E. Q&A: Victor Velculescu. Out for blood. Nature. 2015 May 14;521(7551):S9.

Inventions and Patents:

Inventor of 25 patents issued by the U.S. Patent and Trademark Office and over 49 patent applications under consideration.

1. 9,982,304 ARID1A and PPP2R1A mutations in cancer
2. 9,957,572 Personalized tumor biomarkers
3. 9,926,606 Tyrosine kinome
4. 9,695,479 Medulloblastoma genes as targets for diagnosis and therapeutics
5. 9,637,779 Antisense transcriptomes of cells
6. 9,580,750 P13K pathway mutations in cancer
7. 9,551,037 Consensus coding sequences of human breast and colorectal cancers
8. 9,422,554 MicroRNAome
9. 9,353,418 Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
10. 9,315,868 Diagnostic method using PALB2
11. 9,206,467 Tyrosine kinome
12. 9,012,145 Protein tyrosine phosphatase mutations in cancers
13. 8,709,723 Integrated analyses of breast and colorectal cancers
14. 8,685,660 Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
15. 8,586,725 MicroRNAome
16. 8,394,598 Tyrosine kinome
17. 8,039,210 Protein tyrosine phosphatase mutations in cancers
18. 8,026,053 Mutations of the PIK3CA gene in human cancers
19. 7,704,687 Digital karyotyping
20. 7,504,493 Characterization of the yeast transcriptome
21. 6,746,845 Method for serial analysis of gene expression
22. 6,498,013 Serial analysis of transcript expression using MmeI and long tags
23. 6,383,743 Method for serial analysis of gene expression
24. 5,866,330 Method for serial analysis of gene expression
25. 5,695,937 Method for serial analysis of gene expression

Inventor of methods or gene targets currently used in clinical diagnostic testing or as a target for FDA-sanctioned clinical testing. These include

1. Genetic alterations in isocitrate dehydrogenase (IDH) and other genes in human cancer
2. Mutations of the PIK3CA gene in human cancers
3. Digital karyotyping
4. Personalized tumor biomarkers

Technology Transfer:

1997 – 2006 Consultant, Genzyme Corporation
2003 – 2012 Scientific Advisory Board, SoftGenetics, Inc.
2007 – 2012 Scientific Advisory Board, Helicos BioSciences
2009 – 2013 Founder and Scientific Advisory Board, Sysmex/Inostics
2010 – 2016 Founder, CSO, interim CEO, Personal Genome Diagnostics
2010 – present Founder, Member of Board of Directors, Personal Genome Diagnostics
2012 – 2013 Scientific Advisory Board, Quintiles
2015 Scientific Advisory Board, Janssen Diagnostics
2016 – present Scientific Advisory Board, Ignyta

EDUCATIONAL ACTIVITIES

Teaching

1996 – present Short Course in Medical and Experimental Mammalian Genetics, The Jackson Laboratories, Bar Harbor, Maine (1996, 2007, 2010 – present)
1999 – 2000 Course for Advanced Genomic Techniques, EMBL, Heidelberg, Germany
2005 – present Annual course, Advanced Topics in Human Genetics, Johns Hopkins University
2007 – 2013 Annual core discussion course in Cellular and Molecular Medicine, Johns Hopkins University
2007 Special Topics in Cancer Biology, Univ. of Maryland School of Medicine

Graduate programs:

2002 – present Faculty member, Program in Human Genetics and Molecular Biology, Johns Hopkins University School of Medicine
2004 – present Faculty member, Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine
2008 – present Faculty member, Postdoctoral Training Program in Areas Fundamental to Cancer Research, Johns Hopkins University Bloomberg School of Public Health

Editorial Activities:

Peer reviewer for manuscripts submitted to over 25 journals including Cell, Cancer Cell, Cancer Research, Cancer Discovery, Nature, Nature Biotechnology, Nature Cell Biology, Nature Communications, Nature Genetics, Nature Medicine, Nature Methods, New England Journal of Medicine, Science, Science Translational Medicine

Editorial Board Positions

2000 – 2001 Editorial Associate, Medicine
2005 – 2008 Editorial Board, Genome Research
2007 – present Editorial Board, Journal of Cellular and Molecular Medicine
2008 – 2010 Editorial Board, Pathogenetics
2008 – present Editorial Board, Carcinogenesis
2013 – present Editorial Board, Discoveries
2014 – 2016 Editorial Board, Cancer Discovery

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

1992 – 1995 Educational Policy and Curriculum Committee
The Johns Hopkins University School of Medicine
1998 – 1999 Subcommittee on Medical Education and Accreditation
The Johns Hopkins University School of Medicine
2003 – 2011 Fellow’s Day Awards Selection Committee
Johns Hopkins Kimmel Cancer Center
2004 – 2010 Young Investigators’ Day Awards Selection Committee
Johns Hopkins University School of Medicine
2007 – 2010 Howard University / Johns Hopkins Internal Advisory Committee
2007 – 2014 Lab Shared Resources Committee, Johns Hopkins Kimmel Cancer Center
2008 Research Impact Study Group, Johns Hopkins University School of Medicine
2009 – present Executive Leadership Council, Johns Hopkins Kimmel Cancer Center
2009 – present Research Council, Johns Hopkins Kimmel Cancer Center
2011 Johns Hopkins High Throughput Biology Center Scientific Review
2014 Technology Advisory Committee, Johns Hopkins School of Medicine
2012 – present Committee on Conflict of Interest, Johns Hopkins School of Medicine
2016 – present Executive Oversight Committee, Johns Hopkins Kimmel Cancer Center

National/International Committees and Conferences

1995 – present American Association for Advancement of Science
1999 – 2000 Workshop Organizer, Annual EMBL Practical Course: Genome Analysis using High Throughput Techniques. Heidelberg, Germany.
2000 – 2005 Conference Chairman, Annual SAGE Conferences on Gene Expression Analyses. Baltimore, San Diego, Amsterdam, and Boston.
2006 Science and GE Healthcare Young Scientist Prize Selection Panel
2006 Conference Chairman, Cancer Genomics and Emerging Technologies Conference, Boston, MA, October 2–4, 2006.
2007 Chair, 2007 AACR Annual Meeting Educational Session, Los Angeles, CA.
2008 External Advisory Panel, NCI Laboratory of Experimental Carcinogenesis
2008 – present Member, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation Core Cancer Program Member
2008 Conference Co-Chair, Lustgarten Foundation Think Tank, Pancreatic Cancer Genome sequencing: What’s Next? Baltimore, MD.
2009 – 2011 International Cancer Genome Consortium (ICGC) Working Group
2009 Ontario Institute of Cancer Research Program Review Panel
2009 AACR Grants for Translational Breast Cancer Research Review Committee
2009 Chair, 2009 AACR Annual Meeting New Concepts in Organ-Site Research Session: Colon Cancer Biology, Genetics, and Early Detection Denver, CO
2009 Session Chair, The Biology of Genomes Meeting, Cold Spring Harbor, NY
2010 Search Committee for Director of NCI Center for Cancer Genomics
2010 Chair, 2010 AACR Annual Meeting Methods Workshop on Next Gen Sequencing: Data Analysis and Applications, Washington, DC
2010 AACR Molecular Genetics Subcommittee of the Cellular and Molecular Biology Section of the 2011 Program Committee
2011– present Sir William Osler’s Interurban Clinical Club
2011– present American Association of Cancer Research
2011 AACR Annual Meeting Program Committee
2012 AACR Educational Committee
2012 – 2014 Chair, AACR Basic Cancer Research Fellowship Scientific Review Committee
2013 Chair, 2013 AACR Annual Meeting Minisymposium: Genome-Based Discovery in Human Cancer
2013 Chair, 2013 AACR Annual Meeting Major Symposium: Blood-Based Molecular Analysis of Cancer
2014 – 2015 Co-Chairperson, AACR International Conference on Frontiers in Basic Cancer Research
2014 – 2015 Co-Chairperson of the 2015 AACR Annual Meeting Program Committee
2015 Chair, 2015 AACR Annual Meeting Major Symposium: Liquid biopsy approaches for detecting, monitoring, and characterizing human cancer
2015 – present Co-Leader, SU2C-Dutch Cancer Society Colorectal Cancer Dream Team: Molecular Early Detection of Colorectal Cancer
2016 Chair, Molecular Medicine TRI-CON 2016 Meeting, Personalized Diagnostics Session
2016 – 2017 Chair, AACR Regulatory Science and Policy Subcommittee
2016 – present Chair, AACR Publications Committee
2018 – present Co-Chair, AACR Committee on Conflict of Interest Guidelines

National/International Advisory Boards

2006 – 2007 The Cancer Genome Atlas (TCGA) Advisory Panel
2006 – 2007 Multiple Myeloma Research Consortium Advisory Panel
2009 – 2015 Starr Cancer Consortium Scientific Review Board
2012 – present External Advisory Board, Basser Research Center, University of Pennsylvania
2013 NHGRI Cancer Genetics Branch Site Visit and Quadrennial Review
2013 – 2016 AACR Board of Directors
2016 White House Cancer Moonshot Blue Ribbon Panel Working Group on Precision, Prevention and Early Detection
2016 – present External Advisory Board, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
2017 – present External Advisory Board, Cancer Research UK Manchester Institute
2017 – 2020 Scientific Advisory Committee, Ludwig Cancer Research
2017 – 2020 Scientific Advisory Committee, The Mark Foundation
2018 – 2025 Scientific Advisory Board, Academy of Finland Center of Excellence in Tumor Genetics Research
2018 – present External Advisory Board, Dana Farber Cancer Institute / Harvard Cancer Center

LECTURES AND PRESENTATIONS

Keynote Presentations and Named Lectures

1. Amersham/Pharmacia Biotech & Science Young Scientist Prize Award Symposium. Tantalizing transcriptomes – SAGE and its use in global gene expression analysis. University of Uppsala Uppsala , Sweden, December 9, 1999.
2. Keynote Speaker, Human Genome Organization (HUGO) SAGE Workshop. Transcriptome Analysis using SAGE. Hilversum, The Netherlands, January 29- February 1, 1999.
3. Reynolds Lecture, Johns Hopkins University Cardiovascular Clinical Research Center. Analysis of human transcriptomes using SAGE. Baltimore, MD, October 19, 2004.
4. Keynote Speaker, University of Texas Program in Human and Molecular Genetics 9th Annual Mini-Symposium. Mutational analysis of signaling pathways in colorectal cancer. MD Anderson Cancer Center, Houston, Texas, February 11, 2005.
5. Sir William Osler Young Investigator Award Lecture: Genetic analysis of signaling pathways in human cancer. 193rd Meeting of the Interurban Clinical Club. Baltimore, MD, April 7, 2006.
6. Distinguished Invited Speaker, Cell Biology Students’ Association at the University of Alberta, Edmonton, Canada. Blueprint of breast and colorectal cancer genomes. May 19, 2007.
7. Keynote Speaker, 17th World Congress of the International Association of Surgeons, Gastroenterologists, and Oncologists. Blueprint of the colorectal cancer genome. Bucharest, Romania, September 5-8, 2007.
8. Keynote Speaker, AACR Molecular Diagnostics in Cancer Therapeutic Development. Blueprint of the breast and colorectal cancer genomes. Atlanta, GA, September 17, 2007.
9. 20th European Association for Cancer Research (EACR) Meeting. Carcinogenesis Young Investigator Award Lecture. Lyon, France, July 8, 2008.
10. New York University School of Medicine Honors Program Lecture. Integrated genomic analyses of human cancer. New York, January 12, 2009.
11. AACR Outstanding Achievement in Cancer Research Award Lecture, AACR Annual Meeting, Denver, Colorado, April 22, 2009.
12. Keynote Speaker, ASCO Gastrointestinal Cancers Symposium. Integrated genomic analyses in human cancer. Orlando, FL, January 24, 2010.
13. Keynote Speaker, US Oncology Annual Research Forum, Personalized genomic analyses of human cancer. Dallas, TX, September 15, 2011.
14. Memorial Sloan-Kettering Cancer Center. The Paul Marks Prize for Cancer Research Presentation. New York, NY, December 1, 2011.
15. Keynote Speaker, IASGO 2013 World Congress, Personalized Genomic Analysis of Human Cancer, Bucharest, Romania, September 18-21, 2013.
16. Mt. Sinai Medical Center Frontiers in Oncology Seminar, Genomic Analyses of Cancer in Tissue and Liquid Biopsies, New York, March 25, 2015.
17. Keynote Speaker, Cancer Biology Program of the University of Maryland. Personalized Genomic Analyses of Human Cancer, Baltimore, MD, May 18, 2015.
18. Keynote Speaker, AACR Metabolism and Cancer Meeting, Insights into cancer metabolism through personalized genomic analyses. Bellevue, Washington, June 7-10, 2015.
19. Keynote Speaker, Liquid Biopsy Approaches for Detection and Characterization of Human Cancer. Cambridge Healthtech Insitute Next Generation Dx Summit. Washington, DC, August 18-19, 2015.
20. Keynote Speaker, Genomic Analyses of Cancer, The Genomics of Common Diseases, Baltimore, MD, 2016
21. Keynote Speaker, Johns Hopkins Greenberg Bladder Cancer Institute / American Urological Association Translational Research Conference, Baltimore, MD, March 8, 2018.
22. Carol and Dick Hertzberg Prize Lecture, University of California, San Diego. Early Detection and Characterization of Cancer Using Noninvasive Liquid Biopsies. San Diego, CA, September 13, 2018.
23. Keynote Speaker, Pancreatic Cancer Precision Medicine Program Retreat, Baltimore, MD, September 17, 2018.

Invited Lectures

1. American Heart Association Student Fellowship Conference. Structural analysis of the mannose-6-phosphate receptor. San Jose, California, August 1990.
2. Stanford University Department of Biological Sciences Aschauer Honors Symposium. Identification of an endosome retention signal in the mannose 6-phosphate receptor. Stanford, California, June, 1992.
3. Human Genome Organization (HUGO) Human Genome Meeting ’96. Analysis of the cancer genome with SAGE. Heidelberg, Germany, March 22, 1996.
4. Johns Hopkins University Human Genetics Soup Conference. Analysis of gene expression patterns in cancer and yeast with SAGE. Baltimore, Maryland, May 28, 1996.
5. National Institute of Neurological Disorders and Stroke Seminar. Analysis of gene expression patterns in cancer and yeast with SAGE. Bethesda, Maryland, June 12, 1996.
6. Short Course in Medical and Experimental Mammalian Genetics. Serial analysis of gene expression. Jackson Laboratory, Bar Harbor, Maine, July 15-26, 1996.
7. National Institutes of Health Selected Topics in Gene Expression and Transcriptional Regulation. Serial analysis of gene expression. Bethesda, Maryland September 19, 1996.
8. After the Genome 2: Towards a Predictive Functional Genomics. Analysis of yeast and cancer transcriptomes. Santa Fe, New Mexico, November 9-12, 1996.
9. American Society of Microbiology Conference – Yeast Genetics and Human Disease. Analysis of gene expression in yeast with SAGE. Baltimore, Maryland, November 14-17, 1996.
10. FAES Biotechnology Course National Institutes of Health. Serial analysis of gene expression. Bethesda, Maryland, February 27, 1997.
11. Washington University School of Medicine Department of Genetics Seminar. Analysis of gene expression in yeast and cancer with SAGE. St. Louis, Missouri, March 3, 1997
12. William Beaumont Hospital Symposium on DNA Technology in the Clinical Laboratory. Analysis of cancer with SAGE. Royal Oak, Michigan, March 14-15, 1997.
13. American Red Cross Holland Laboratories Topics in Gene Analysis Seminar Series. Analysis of gene expression in yeast and cancer with SAGE. Bethesda, Maryland, April 9, 1997.
14. Fifteenth Annual State University of New York at Stony Brook Symposium on Molecular Biology. Analysis of yeast and cancer transcriptomes. New York, May 19-20, 1997.
15. Genetics Institute Discovery Research Retreat. Serial analysis of gene expression. Ogunquit, Maine, May 21-23, 1997.
16. UNESCO Conference on Contemporary Science. Serial analysis of gene expression. Brasov, Romania, May 27-31, 1997.
17. National Cancer Institute Seminar. High-throughput gene expression analysis with SAGE. National Institutes of Health, Bethesda, Maryland, September 18, 1997.
18. IBC Biochip Conference. Serial Analysis of Gene Expression. Annapolis, Maryland, October 7-8, 1997.
19. Parke-Davis / University of Michigan Symposium on Genomics, Human Genetics, and Human Health. Analysis of Gene Expression in Yeast and Cancer. Ann Arbor, Michigan, October 9, 1997.
20. After the Genome 3. High Throughput Gene Expression Analysis using SAGE. Santa Fe, New Mexico, October 25-27, 1997.
21. Novartis Pharmaceuticals Workshop on Discovery of Differentially Expressed Genes and Functional Analysis. High Throughput Gene Expression Analysis using SAGE. Parsippany, New Jersey, October 28, 1997.
22. American Society of Human Genetics 47th Annual Meeting. Serial Analysis of Gene Expression (SAGE). Baltimore, Maryland, October 28 – November 1, 1997.
23. Roche Molecular Systems Seminar. High Throughput Gene Expression Analysis using SAGE. Alameda, California, December 22, 1997.
24. Tokyo Genome Center International Workshop on Advanced Genetics. Gene Expression Analysis using SAGE. Tokyo, Japan, March 27-28, 1998.
25. Gordon Conference on Clinical and Experimental Chemotherapy. Serial Analysis of Gene Expression. New London, New Hampshire, July 26-30, 1998.
26. AACR 90th Annual Meeting. Use of Serial analysis of gene expression (SAGE) for quantitative cataloging of expressed genes in human disease states. Philadelphia, Pennsylvania, April 10-14, 1999.
27. EMBL Course for Advanced Genomic Techniques. Analysis of transcriptomes using SAGE. Heidelberg, Germany, December 2, 1999.
28. University of Maryland Medical School Department of Microbiology and Immunology Seminar Series. Analysis of transcriptomes using SAGE. Baltimore, MD November 9, 2000.
29. William Beaumont Hospital DNA Technology in the Clinical Laboratory 10th Annual Seminar. Transcriptome analysis of human cancer. Royal Oak, Michigan. March 8-10, 2001.
30. NIH annual SPORE Meeting. SAGE analysis of human cancer. Washington, DC, August, 2001.
31. SAGE 2002 Conference. Using SAGE to explore the genome. Coronado Island, San Diego, California, September 8-11, 2001.
32. Roswell Park Cancer Institute Fourth Annual Oncological Sciences Symposium: Modeling Tumor Expression Profiles for Intervention. SAGE analysis of colorectal cancer. Buffalo, New York, November 5-6, 2001.
33. American Association for the Advancement of Science 2002 Annual Meeting. How many genes in the genome? Boston, Massachusetts, February 14-19, 2002.
34. NHGRI planning workshop on relating genetic variation to health and disease. Allelic variation in gene expression. Bethesda, Maryland August 8-9, 2002.
35. SAGE 2003 Annual Meeting. Using SAGE and digital karyotyping to explore the genome University of Amsterdam Academic Medical Center, Amsterdam, The Netherlands January 17-19, 2003.
36. Columbia University Institute of Cancer Genetics Seminar. Mutational analysis of the colorectal cancer genome. New York, New York, June 26, 2003.
37. Research Matters Conference of the Maryland Cigarette Restitution Fund. Mutational analysis of the tyrosine kinome. Baltimore, Maryland, November 13, 2003.
38. The Johns Hopkins Kimmel Cancer Center Translational Research Conference. Mutational analysis of the colorectal cancer genome. Baltimore, Maryland, November 19, 2003.
39. NCI/NHGRI Workshop on Exploring Cancer through Genomic Sequence Comparisons. Genetic analysis of human cancers. Bethesda, Maryland, April, 2004.
40. The Johns Hopkins University School of Medicine Dermatology Grand Rounds. Mutational analysis of the colorectal cancer genome. Baltimore, Maryland, September 15, 2004.
41. Genome Sequencing and Analysis Conference (GSAC VXI). Mutational analysis of the colorectal cancer genome. Washington, DC, September 27-30, 2004.
42. SAGE 2004 – Decoding the ‘OMES. Mutational analysis of the colorectal cancer genome. Fairmont Copley Hotel, Boston, Massachusetts, September 30 – October 3, 2004.
43. Dana Farber Cancer Center and Harvard Medical School Seminar Series. Mutational analysis of the colorectal cancer genome. Boston, Massachusetts, October 5, 2004.
44. University of Pennsylvania Hematology/Oncology Seminar Series. Mutational analysis of the colorectal cancer genome. Philadelphia, Pennsylvania, October 12, 2004.
45. AAAS Annual Meeting Symposium on Personalized Healthcare. Mutational analysis of signaling pathways in colorectal cancer. Washington, DC, February 19, 2005
46. Johns Hopkins University School of Medicine Course on Current Concepts in the Multidisciplinary Management of Colorectal Cancer. Molecular genetics of colorectal cancer: clinical implications. Baltimore, MD, March 31-April 1, 2005
47. The Johns Hopkins Kimmel Cancer Center Biology of Cancer Seminar Series. Kinases and Phosphatases in colon cancer. Baltimore, MD, April 13, 2005.
48. NHGRI / NCI Workshop “Toward a Comprehensive Genomic Analysis of Cancer.” Systematic mutational analyses: using genomics to differentiate tumors. Washington, DC, July 20-22, 2005.
49. United States Congressional Briefing organized by the American Association of Medical Colleges. Using genomics to understand and treat human cancer. Washington, DC July 29, 2005.
50. Pew Charitable Trusts Biomedical Scholars Annual Meeting. Mutational analysis of signaling pathways in human cancer. Costa Rica, March 4-9, 2006.
51. AACR 97th Annual Meeting. Genetic analysis of signaling pathways in colorectal cancer. Washington, DC, April 3, 2006.
52. Novartis Pharmaceuticals Advisory Board Meeting on PI3K Inhibitors. PI3K mutations: incidence and relevance for targeted therapy of human cancer. New York, NY, April 27-28, 2006.
53. General Motors Cancer Research Awards Annual Scientific Conference “Genomics and Cancer”. Mutational analysis of signaling pathways in human cancer. Bethesda, MD, June 12-13, 2006.
54. Johns Hopkins Bloomberg School of Public Health Biostatistics Grand Rounds. Genomic analysis of human cancer. Baltimore, MD, September 13, 2006.
55. Health Affairs Cancer Genomics Meeting at the National Academy of Sciences. Blueprint of breast and colorectal cancer genomes. Washington, DC, September 19, 2006.
56. Cancer Genomics and Emerging Technologies Meeting. Genomic analyses of human cancer. Boston, MA, October 2, 2006.
57. 3rd International Meeting on Tumor Progression and Therapeutic Resistance. Blueprint of breast and colorectal cancer genomes. Baltimore, MD, October 23, 2006.
58. National Institute on Aging Seminar Series. Blueprint of breast and colorectal cancer genomes. Baltimore, MD, November 2, 2006
59. Friedrich Meischer Institute Symposium “Targeting the Kinome” Symposium. Genomic analysis of breast and colorectal cancers. Basel, Switzerland. December 2-4, 2006.
60. Memorial Sloan-Kettering Cancer Center Cancer Biology and Genetics Seminar. Genomic analyses of human cancer. New York, NY, February 2, 2006.
61. State of Maryland Senate Budget and Tax Committee Hearing. Cigarette Restitution Fund Research Program at Johns Hopkins University. Annapolis, MD, March 7, 2007.
62. AACR 98th Annual Meeting. Genomic analysis of breast and colorectal cancers. Los Angeles, CA, April 16, 2007.
63. Johns Hopkins University Department of Pathology Grand Rounds. Mutational analyses of human cancer. Baltimore, MD, April 30, 2007.
64. Agencourt Biosciences Invited Speaker. Large scale sequence analysis of human cancer. Beverly, MA, May 2, 2007.
65. Short Course in Medical and Experimental Mammalian Genetics. Genomic analyses of human cancer. Jackson Laboratory, Bar Harbor, Maine, July 15-27, 2007.
66. National Cancer Institute 15th Annual SPORE Investigator’s Workshop. Genomic analyses of colorectal cancer. Baltimore, MD, July 7-10, 2007.
67. International Cancer Genomics Consortium Meeting. The Johns Hopkins Cancer Genome Project. Toronto, Canada, Oct 1-2, 2007
68. National cancer Institute Laboratory of Experimental Carcinogenesis invited Seminar Speaker. Blueprint of the breast and colorectal cancer genomes. Bethesda, MD, November 30, 2007.
69. University of Geneva Department of Genetics Seminar Speaker. Blueprint of the breast and colorectal cancer genomes. Geneva, Switzerland, Jan. 16, 2008.
70. Case Western Reserve University Blood Seminar Speaker. Blueprint of the breast and colorectal cancer genomes. Cleveland, Ohio, Jan 25, 2008.
71. Columbia University Institute of Cancer Genetics Seminar. Mutational analyses of human cancer. New York, New York, Feb 19, 2008.
72. Pew Scholars Annual Meeting. Genomic analyses of human cancer. Aruba, March 8-13, 2008.
73. Johns Hopkins University School of Public Health, Department of Biochemistry and Molecular Biology Seminar Speaker. Blueprint of breast and colorectal cancer genomes. March 17, 2008.
74. 3rd Mildred Scheel Cancer Conference. Genomic analyses of human cancer. Bonn, Germany, June 18, 2008.
75. Wellcome Trust and Nature Genetics Conference on Genomics of Common Diseases. Genomic analyses of human cancer. Boston, MA, September 6-9, 2008.
76. University of Toronto Ontario Cancer Institute Seminar. Analyses of brain and pancreatic cancer genomes. Toronto, Canada, September 17, 2008.
77. Lennox K. Black Symposium for Transformational Discoveries in Cancer. Genomic analyses of human cancer. Philadelphia, PA, November 10, 2008.
78. University of Pennsylvania / Children’s Hospital of Pennsylvania Oncology Seminar Series. Integrated Genomic Analyses of Human cancer. December 9, 2008.
79. AACR New Concepts in Organ Site Research – Colon Cancer Biology, Genetics and Early Detection. Genomic landscapes of colorectal cancer. Denver, Colorado, March 21, 2009.
80. Lilly Foundation 15th Annual Symposium. The genomic landscapes of human cancer. San Lorenzo de El Escorial, Madrid, Spain, March 26, 2009.
81. NCI/NINDS Cancer Cell Metabolism Workshop. Intersection between genetic alterations and metabolism in human cancer. Bethesda, MD, July 9-10, 2009.
82. Institute for Cancer Research and Treatment Seminar Speaker. Genomic analyses of human cancer. Candiolo (Torino), Italy, July 24, 2009.
83. Ludwig Institute for Cancer Research Brain Cancer Meeting. Integrated genomic analyses of human cancer. Rockville, MD, September 17, 2009.
84. Howard-Hopkins Joint Scientific Symposium. Genomic landscapes of human cancer. Baltimore, MD, December 14, 2009.
85. Johns Hopkins University School of Medicine Department of Molecular Biology and Genetics. Integrated genomic analyses of human cancer. Baltimore, MD, October 29, 2009.
86. University of Michigan Cancer Center Annual Symposium. Genomic analyses of human cancer. Ann Arbor, MI, Nov 13, 2009.
87. NIH Symposium “Translational Genomics: Looking Back and Moving Forward ”. Integrated genomic analyses of human cancer. Bethesda, MD, March 4, 2010.
88. Johns Hopkins University Department of Biological Chemistry Research Seminar. Baltimore, MD, March 16, 2010.
89. Johns Hopkins Medicine Town Meeting. Genome-based personalized blood test for cancer. Baltimore, MD, April 20, 2010.
90. Ludwig Institute for Cancer Research Symposium on Next Generation Sequencing. Personalized genomic analyses in human cancer. Baltimore, MD, June 3, 2010.
91. Sidney Kimmel Cancer Center Breast Cancer Program. Personalized genomic analyses in human cancer. Baltimore, MD, June 15, 2010.
92. 51st Annual Short Course on Medical and Experimental Genetics. Cancer biology exposed through large-scale sequencing. Bar Harbor, Maine, July 23, 2010.
93. Sanger Center Seminar. Integrated genomic analyses of human cancer. Hinxton, United Kingdom, July 30, 2010.
94. 4th Annual Young Investigator Symposium in Genomics and Bioinformatics. Integrated analyses of the first 100 cancer genomes. Baltimore, MD, September 23, 2010.
95. ASCO Annual Meeting on Molecular Markers in Cancer. New approaches for discovery of molecular biomakers. Hollywood, FL, October 18, 2010.
96. Johns Hopkins University Department of Medicine Grand Rounds. Integrated genomic analyses of human cancer. Baltimore, MD, October 22, 2010.
97. 25th Annual Forbeck Foundation Forum on “Cancer Genomics”. Hilton Head, SC, Nov 5, 2010.
98. Johns Hopkins University Dean’s Retreat on Personalized Medicine. Personalized genomic analyses of human cancer. St. Michaels, MD. November 20, 2010.
99. DKFZ Brain Tumor Network Plus Symposium. Personalized genomic analyses of human cancer. Heidelberg, Germany. December 13, 2010.
100. TGEN Sequencing the Genome Meeting. A primer for the Practicing Physician. Phoenix, AZ. February 11, 2011.
101. Eighth Molecular Diagnostics Conference. Personalized genomic analyses of human cancer. San Francisco, CA. February 24, 2011.
102. University of Pittsburgh 25th Anniversary Symposium “Cancer Genomics and the Impact of Next Generation Sequencing.” Pittsburgh, PA. March 10, 2011
103. International Thyroid Oncology Group (ITOG) Meeting. Genomic Analyses of Human Cancer. Baltimore, MD, May 2, 2011
104. Pancreatic Cancer Research Team ASCO Meeting. Chicago, IL, June 2, 2011.
105. Quintiles “Full Circle Oncology: From Cancer Genomic and Proteomic to Treatment Decisions” ASCO Meeting. Chicago, IL, June 4, 2011.
106. Keystone Symposia meeting on “Changing Landscape of the Cancer Genome”. Boston, July 23, 2011.
107. Beckman Coulter Science & Technology Symposium. Genomic Analyses of Human Cancer and the Need for Integrated Diagnostic Approaches. La Brea, CA, July 6-7, 2011.
108. Short Course in Medical and Experimental Mammalian Genetics. Cancer Biology Exposed by Large-Scale Sequencing. Jackson Laboratory, Bar Harbor, Maine, July 17-29, 2011.
109. The Lancet, Oncology at the Limits II Conference. Personalized genomic analyses of human cancer. Stockholm, Sweden, October 15, 2011.
110. Evolving Views of Neoplastic Gastro-Enteric Pathology. Genomic Analyses of GI Cancers. Paris, France, Nov 3-5, 2011.
111. University of Pennsylvania Abramson Family Cancer Research Institute Seminar. Personalized Genomic Analyses of Human Cancer. Nov 15, 2011.
112. Duke University Preston Robert Tisch Brain Tumor Center. Personalized genomic analyses of human cancer. Durham, NC, December 14, 2011.
113. Stanford University Department of Genetics Seminar Series. Genomic Analysis of Cancer. Stanford, CA, January 2-4, 2012.
114. NCI Division of Cancer Biology. Overview of Cancer Genetics. Bethesda, MD, March 12, 2012.
115. AACR Methods Workshop: Next-Generation Sequencing: Issues Moving into The Clinical Arena. Chicago, IL, March 31, 2012.
116. Penn State Hershey Cancer Institute. Personalized genomic analyses of human cancer. Hershey, PA, May 10, 2012.
117. UCSF Cancer Center Seminar Series. Personalized genomic analyses of human cancer. San Francisco, CA, June 15, 2012.
118. 53rd Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer Biology Exposed by Large-Scale Sequencing. Jackson Laboratory, Bar Harbor, Maine, July 20, 2012.
119. IBC Life Sciences Next-Gen Sequencing Applications and Translational Technologies Summit. Personalized Genomic Analyses of Human Cancer. San Francisco, CA, August 7, 2012.
120. Mayo Clinic Center For Individualized Medicine. Personalized Genomic Analyses of Human Cancer. Rochester, MN, September 24, 2012.
121. NCI Pancreatic Cancer: Scanning the Horizon for Focused Interventions. Genetics of Pancreatic Cancer. Bethesda, MD, October 23, 2012.
122. Special Seminar, Department of Genetics, Harvard Medical School. Personalized Genomic Analysis of Human Cancer. Cambridge, MA, February 26-28, 2013.
123. Frontiers in Cancer Research and Therapy, Karolinska Institutet. Personalized Genomic Analysis of Human Cancer. Stockholm, Sweden, March 7-8, 2013.
124. The 1st Internationals Congress on Controversies in Personalized Oncology. Is it prime time for use of NGS in the clinic? Barcelona, Spain. March 3-7, 2013.
125. AACR Annual Meeting 2013. Detection of chromosomal alterations in cell free DNA of cancer patients. Washington, DC, April 6-10, 2013.
126. 4th Annual Origins of Cancer Symposium, Van Andel Institute. Personalized Genomic Analysis of Human Cancer. Grand Rapids, MI, May 2-3, 2013.
127. Sexta Lección Conmemorativa Clara Campal Lecture, Centro Nacional de Investigaciones Oncológicas. Personalized Genomic Analysis of Human Cancer. Madrid, Spain, June 13, 2013.
128. 54th Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer biology exposed by large-scale sequencing. Bar Harbor, Maine, July 21-August 2, 2013.
129. Prostate Cancer Foundation 20th Annual Scientific Retreat. Personalized Genomic Biomarkers for Cancer Progression and Survival. National Harbor, MD, October 24-26, 2013.
130. AACR-AdvaMedDx Cancer Diagnostics Conference, Detection and Prognosis: The Cutting Edge, Washington, DC, October 29, 2013.
131. 8th Annual Circulating Nucleic Acids in Plasma Conference. Whole Genome Analyses of Circulating Tumor DNA. Baltimore, MD, November 7-8, 2013.
132. Scripps Research Research Institute, Cancer Affinity Group Seminar. Personalized Genomic Analyses of Human Cancer. San Diego, CA, April 3, 2014.
133. AACR Annual Meeting SU2C Scientific Session. Pancreatic Cancer Dream Team Report: Realizing Patient Benefit. San Diego, CA, April 7, 2014.
134. AACR ASCO Symposium on Precision Medicine. Personalized Genomic Analyses of Human Cancer. San Diego, CA, April 7, 2014.
135. AACR Annual Meeting Meet the Expert Session. Cancer Genome Landscapes through Tissue and Blood Based Molecular Analyses. San Diego, CA, April 8, 2014.
136. 55th Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer biology exposed by large-scale sequencing. Bar Harbor, Maine, July 25, 2014.
137. Next Generation Dx Summit. Personalized Genomic Analyses of Human Cancer. Washington, D.C., August 20, 2014.
138. AACR-ASCO-BCRF-FDA Breast Cancer Workshop. What is the Utility of Liquid Biopsies in a Genomically-Driven Trial? Bethesda, MD, October 21, 2014.
139. Cancer Steering Committee Annual Meeting. Strategies for Inclusion of Circulating Nucleic Acids. Gaithersburg, MD, October 23-24, 2014.
140. Interurban Clinical Club Scientific Meeting. Liquid Biopsy Approaches for Detecting and Characterizing Human Cancer. Baltimore, MD, November 7, 2014.
141. AMP Annual Meeting. Liquid Biopsy Approaches for Detecting and Characterizing Human Cancer. Washington, D.C., November 13-15, 2014.
142. KWF/SU2C Dream Team Meeting. Liquid Biopsy Approaches for Detecting and Characterizing Human Cancer. Amsterdam, The Netherlands, November 18-19, 2014.
143. SYSCOL Annual Meeting. Genomic Landscape of Therapeutic Response in Colorectal Cancer. Wolfebuettel, Germany, November 19-21, 2014.
144. AACR SU2C Pancreatic Dream Team Meeting. Clinically Actionable Genetic Alterations in Pancreatic Cancer. Baltimore, MD, December 14-15, 2014.
145. Johns Hopkins Pathology Grand Rounds. Genomic Analyses of Cancer in Tissue and Liquid Biopsies. Baltimore, MD, Jan 12, 2015.
146. TRICON Meeting, Liquid Biopsies for Cancer Detection and Characterization. San Francisco, CA, Feb 17, 2015
147. FDA Next Generation Sequencing Workshop. Analytical Performance of NGS Tests in Cancer. Bethesda, MD, Feb 20, 2015
148. Massachusetts General Hospital Seminar. Genomic Analyses of Cancer in Tissue and Liquid Biopsies. Boston, MA, April 8, 2015
149. AACR Annual Meeting. Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation, Philadelphia, PA, April 18, 2015.
150. AACR Annual Meeting. Liquid Biopsy Approaches for Characterizing Cancer Genomes. Philadelphia, PA, April 21, 2015.
151. ASCI / AAP Join Meeting. Liquid Biopsy Approaches for Detecting and Characterizing Cancer Genomes. Chicago, April 24, 2015.
152. 56th Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer biology exposed by large-scale sequencing. Bar Harbor, Maine, July 24, 2015.
153. NOCRC Steering Group Meeting. Liquid Biopsy Approaches for Characterizing Cancer Genomes. Aarhus University, Aarhus, Denmark, September 7, 2015.
154. 40th Anniversary Symposium of the Johns Hopkins University Medical Scientist Training Program. Genomic Analyses of Human Cancer. Baltimore, MD, October 30, 2015.
155. SU2C MEDOCC Dream Team Meeting. Liquid Biopsy Approaches for Characterizing Cancer Genomes. Amsterdam, November 10, 2015.
156. Netherlands Cancer Institute (NKI) Seminar. Liquid Biopsy Approaches for Characterizing Cancer Genomes. Amsterdam, November 11, 2015.
157. Georgetown Lung Cancer Meeting. The Promise and Challenges of Molecular Diagnostics. Washington, DC, December 4, 2015.
158. FDA Public Workshop on NGS Testing. Analytical Performance and Quality of NGS Tests in Cancer. Bethesda, MD, Jan 8, 2016.
159. Cambridge Healthtech Institute Webinar. Cancer Genomics and Neo-Antigens in Immunotherapy. Baltimore, MD, February 16, 2016.
160. Princeton University Seminar. Analyses of Cancer Genomes. Princeton, NJ, February 18, 2016.
161. The Future of Genomic Medicine IX Conference. Analyses of Cancer Genomes. La Jolla, CA, March 4, 2016.
162. Molecular Medicine TRI-CON 2016 Meeting. Cancer Genome Analyses in Tissue and Liquid Biopsies. San Francisco, CA, March 9, 2016.
163. Johns Hopkins Oncology Grand Rounds. Updates in Clinical and Genomic Advances in Lung Cancer. Baltimore, MD, March 24, 2016.
164. New York Cancer Genomics Research Network Meeting. Genomics in Cancer Care and Prevention. New York, NY, April 5, 2016.
165. AACR Annual Meeting. Genomic Landscape of Response to a Targeted Agent in Late Stage Colorectal Cancer. New Orleans, LA, April 16, 2016.
166. SU2C MEDOCC Dream Team Meeting. Liquid Biopsy Analyses for Cancer Detection. New Orleans, LA, April 19, 2016.
167. Genomics Analysis Symposium, Takeda Pharmaceuticals. Cancer Genome Analyses in Tissue and Liquid Biopsies. Boston, MA, May 2, 2016.
168. ASCO Annual Meeting. Molecular Oncology Tumor Board – Molecular Biologist’s Perspective. Chicago, June 4, 2016.
169. American Molecular Laboratories Symposium. Genomic Signatures of Response and Resistance to Cancer Therapy. Chicago, June 4, 2016.
170. 57th Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer biology exposed by large-scale sequencing. Bar Harbor, Maine, July 22, 2016.
171. Next Generation Dx Summit. Liquid Biopsy Approaches for Characterizing Cancer Genomes. Washington, DC, August 24, 2016.
172. PARADIGM Clinical Trial Boost Up Meeting. Genomic Analyses of Human Cancer. Japan, October 23, 2016.
173. SU2C Summit on Cancer Prevention and Interception. Liquid Biopsies and New Possibilities in Early Detection. San Diego, CA, November 15, 2016.
174. SU2C Scientific Summit Progress Review. Molecular Early Detection of Colorectal Cancer. Anaheim, CA, January 24, 2017.
175. AACR Annual Meeting. Liquid biopsies for detection and characterization of human cancer. Washington DC, April 3, 2017.
176. Adelson Medical Research Foundation Meeting. Liquid biopsies for detection and characterization of human cancer. Las Vegas, Nevada, May 17, 2017.
177. Thoracic Oncology Research Retreat. Predictors of Response and Resistance to Immune Checkpoint Blockade and Targeted Therapy. Baltimore, MD, 2017.
178. Aspen Cancer Conference. Liquid biopsies for detection and characterization of human cancer. Aspen, Colorado, July 17, 2017.
179. 58th Annual Short Course on Medical and Experimental Mammalian Genetics. Cancer biology exposed by large-scale sequencing. Bar Harbor, Maine, July 21, 2017.
180. Cancer Biology Seminar Series. Project GENIE and Clinical Genomics at JHU: Connecting Genotypes to Phenotypes across 20,000 Cancer Patients. Johns Hopkins Kimmel Cancer Center, Baltimore, MD, September 28, 2017.
181. NOCRC Annual Meeting. Direct Detection of Cancers using Circulating Tumor DNA. Aarhus, Denmark, October 2, 2017.
182. The First Helene Ross Bogutz Ovarian Cancer Symposium. Direct Detection of Early Stage Cancers using Circulating Tumor DNA. University of Pennsylvania, Philadelphia, PA, October 16, 2017.
183. 24th Annual Prostate Cancer Foundation Scientific Retreat. Liquid biopsy analyses for detection and characterization of human cancer. Washington, DC, October 5, 2017.
184. SINAInnovations Conference. Panel Discussion on Personalized Omics, Cancer Risk, and Management. Icahn School of Medicine at Mount Sinai, New York, NY, October 18, 2017.
185. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. Genomic Landscape of Response and Resistance to Immune Checkpoint Blockade. Philadelphia, PA, October 27, 2017.
186. The 24th Annual MD State Council on Cancer Control Cancer Conference. Liquid Biopsies and Early Detection of Cancer. Annapolis, MD, November 15, 2017.
187. Symposium and Inaugural Professorial Lecture of Gerrit Meijer. Circulating tumor DNA in diagnostic oncology. University of Utrecht, Utrecht, the Netherlands, November 21, 2017.
188. SU2C Scientific Summit 2018. Molecular Early Detection Of Colorectal Cancer. Santa Monica, CA, January 29, 2018.
189. Translational Research Conference. Early Detection and Characterization of Cancer using Noninvasive Liquid Biopsies. Johns Hopkins Kimmel Cancer Center. Baltimore, MD, February 28, 2018.
190. Johns Hopkins Greenberg Bladder Cancer Institute/American Urological Association Translational Research Conference. Dynamics of Cancer Genomes using Noninvasive Liquid Biopsies. Baltimore, MD, March 8, 2018.
191. CRF Research Grant at Johns Hopkins Institutions Site Visit. Liquid Biopsies and Early Detection of Cancer. Baltimore, MD, April 4, 2018.
192. AACR Annual Meeting 2018. Educational Session: Early detection and characterization of cancer using noninvasive liquid biopsies. Chicago, IL, April 14, 2018.
193. AACR Annual Meeting 2018. Molecular Early Detection of Colorectal Cancer Dream Team: Novel Detection Methodologies. Chicago, IL, April 15, 2018.
194. Oncology Nurses Association 43rd Annual Congress. Precision Oncology and Early Detection using Tissue and Non-invasive Liquid Biopsies. Washington, DC, May 18, 2018.
195. inHealth Moments of Wonder Seminar. Early Detection and Characterization of Cancer Using Noninvasive Liquid Biopsies. Baltimore, MD, May 18, 2018.
196. Johns Hopkins University Board of Trustees Meeting. Liquid Biopsies and Early Detection of Cancer. Baltimore, MD, June 15, 2018.